Mustang Bio Launches CRISPR/Cas9 CAR-T Collaborations with Harvard, BIDMC – Genetic Engineering & Biotechnology News
Endpoints News |
Mustang Bio Launches CRISPR/Cas9 CAR–T Collaborations with Harvard, BIDMC
Genetic Engineering & Biotechnology News Mustang Bio said today it plans to develop CRISPR/Cas9-enhanced chimeric antigen receptor engineered T–cell (CAR-T) therapies for cancer through a license from Harvard University and a research collaboration agreement with Beth Israel Deaconess Medical … CRISPR/Cas9 pioneer Chad Cowan enlists in Mustang Bio's CAR-T … Mustang Bio Announces License Agreement with Harvard University, and Research Collaboration with Beth Israel … |
